Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.87-0.2%$17.67$13.50▼$25.67$4.03B0.542.94 million shs2.79 million shsANIPANI Pharmaceuticals$95.35-0.7%$76.26$52.50▼$96.56$2.07B0.63630,640 shs414,021 shsANVSAnnovis Bio$2.29+0.5%$2.57$1.11▼$10.54$44.62M1.65222,995 shs169,313 shsRVMDRevolution Medicines$40.50+4.0%$37.33$29.17▼$62.40$7.57B1.121.85 million shs1.71 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-2.26%+0.72%-18.15%0.00%ANIPANI Pharmaceuticals0.00%+1.98%+38.17%+53.89%+51.49%ANVSAnnovis Bio0.00%-1.25%-11.54%-28.36%-72.82%RVMDRevolution Medicines0.00%+6.66%+15.88%-1.44%-4.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$16.87-0.2%$17.67$13.50▼$25.67$4.03B0.542.94 million shs2.79 million shsANIPANI Pharmaceuticals$95.35-0.7%$76.26$52.50▼$96.56$2.07B0.63630,640 shs414,021 shsANVSAnnovis Bio$2.29+0.5%$2.57$1.11▼$10.54$44.62M1.65222,995 shs169,313 shsRVMDRevolution Medicines$40.50+4.0%$37.33$29.17▼$62.40$7.57B1.121.85 million shs1.71 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-2.26%+0.72%-18.15%0.00%ANIPANI Pharmaceuticals0.00%+1.98%+38.17%+53.89%+51.49%ANVSAnnovis Bio0.00%-1.25%-11.54%-28.36%-72.82%RVMDRevolution Medicines0.00%+6.66%+15.88%-1.44%-4.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6764.00% UpsideANIPANI Pharmaceuticals 3.10Buy$84.75-11.12% DownsideANVSAnnovis Bio 2.60Moderate Buy$17.33656.58% UpsideRVMDRevolution Medicines 3.00Buy$72.0077.78% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025RVMDRevolution MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$99.009/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.008/21/2025ANIPANI PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$67.008/11/2025ANIPANI PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$65.00 ➝ $77.008/8/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$84.00 ➝ $93.008/8/2025ANIPANI PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.008/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$57.00 ➝ $56.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.44$0.54 per share31.17$1.48 per share11.40ANIPANI Pharmaceuticals$614.38M3.37$7.60 per share12.55$19.11 per share4.99ANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ARVMDRevolution Medicines$11.58M653.77N/AN/A$13.47 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8619.6224.45N/A44.06%41.01%28.47%11/6/2025 (Estimated)ANIPANI Pharmaceuticals-$18.52M-$0.77N/A22.65N/A-1.37%25.03%8.00%11/14/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)Latest ANIP, ADMA, ANVS, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78ANIPANI Pharmaceuticals1.392.541.96ANVSAnnovis BioN/A7.657.65RVMDRevolution Medicines0.1311.7911.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%ANIPANI Pharmaceuticals12.70%ANVSAnnovis Bio20.80%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableANIP, ADMA, ANVS, and RVMD HeadlinesRecent News About These CompaniesRevolution Medicines (NASDAQ:RVMD) Earns Buy Rating from Analysts at Truist FinancialSeptember 7 at 8:13 AM | marketbeat.comGranahan Investment Management LLC Purchases 7,322 Shares of Revolution Medicines, Inc. $RVMDSeptember 7 at 6:20 AM | marketbeat.com59,214 Shares in Revolution Medicines, Inc. $RVMD Purchased by Trexquant Investment LPSeptember 7 at 4:20 AM | marketbeat.comRevolution Medicines, Inc. $RVMD is Checkpoint Capital L.P.'s 3rd Largest PositionSeptember 6 at 8:17 AM | marketbeat.comRevolution Medicines initiated with a Buy at TruistSeptember 6 at 5:19 AM | msn.comTruist Securities Initiates Coverage of Revolution Medicines (RVMD) with Buy RecommendationSeptember 6 at 5:19 AM | msn.comJump Financial LLC Makes New $287,000 Investment in Revolution Medicines, Inc. $RVMDSeptember 6 at 4:19 AM | marketbeat.comJack Anders Sells 4,762 Shares of Revolution Medicines (NASDAQ:RVMD) StockSeptember 5 at 8:23 AM | insidertrades.comBVF Inc. IL Purchases 801,205 Shares of Revolution Medicines, Inc. $RVMDSeptember 5 at 7:56 AM | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Stock Price Up 5.2% - Here's WhySeptember 4 at 1:47 PM | marketbeat.comRevolution Medicines, Inc. $RVMD Stock Holdings Lifted by ADAR1 Capital Management LLCSeptember 4 at 7:41 AM | marketbeat.comParadigm Biocapital Advisors LP Sells 375,000 Shares of Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Stock Holdings Increased by Magnetar Financial LLCSeptember 2, 2025 | marketbeat.comLandscape Capital Management L.L.C. Buys Shares of 17,213 Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comB. Metzler seel. Sohn & Co. AG Acquires 8,622 Shares of Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comRaymond James Financial Inc. Sells 17,994 Shares of Revolution Medicines, Inc. $RVMDSeptember 2, 2025 | marketbeat.comOppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy ProgressSeptember 2, 2025 | insidermonkey.comRevolution Medicines, Inc. $RVMD is DAFNA Capital Management LLC's 3rd Largest PositionSeptember 1, 2025 | marketbeat.comWalleye Capital LLC Has $1.43 Million Position in Revolution Medicines, Inc. $RVMDSeptember 1, 2025 | marketbeat.comRevolution Medicines, Inc. $RVMD Shares Sold by Rafferty Asset Management LLCAugust 31, 2025 | marketbeat.comTema Etfs LLC Grows Holdings in Revolution Medicines, Inc. $RVMDAugust 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Vertical Aerospace: An Analyst's Roadmap to a Potential Re-RatingBy Jeffrey Neal Johnson | August 27, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025ANIP, ADMA, ANVS, and RVMD Company DescriptionsADMA Biologics NASDAQ:ADMA$16.87 -0.04 (-0.24%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$17.08 +0.20 (+1.22%) As of 09/5/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$95.35 -0.65 (-0.68%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$95.30 -0.05 (-0.05%) As of 09/5/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$2.29 +0.01 (+0.48%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$2.30 +0.00 (+0.17%) As of 09/5/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Revolution Medicines NASDAQ:RVMD$40.50 +1.55 (+3.98%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$40.90 +0.40 (+0.99%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
